Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • RG7388: Phase I data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RG7388 Business: Cancer Molecular target: Mdm2 p53 binding protein homolog (MDM2) (HDM2) Description: Oral small …

    Published on 12/15/2014
  • Vocimagene amiretrorepvec: Additional Phase I data

    Tocagen Inc., San Diego, Calif. Product: Vocimagene amiretrorepvec (Toca 511) Business: Cancer Molecular target: NA Description: Retroviral replicating vector delivering the gene encoding cytosine deaminase (CD), an …

    Published on 12/15/2014
  • ABT-122: Phase I data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-122 Business: Autoimmune Molecular target: Interleukin-17A (IL-17A); Tumor necrosis factor (TNF) Description: Dual inhibitor of IL-17A and tumor necrosis factor (TNF) …

    Published on 12/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 12/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 12/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 12/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 12/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 12/8/2014
  • Andexanet alfa: Additional Phase III data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT4445, PRT064445) Business: Cardiovascular Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 12/8/2014
  • BIIB037: Interim Phase Ib data

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Neurimmune Holding AG, Schlieren, Switzerland Product: BIIB037 Business: Neurology Molecular target: Beta amyloid Description: Human anti-beta amyloid mAb Indication: Treat …

    Published on 12/8/2014
  • Brodalumab: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brodalumab (KHK4827) (formerly AMG 827) Business: …

    Published on 12/8/2014
  • cAd3-EBO: Phase I data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. National Institutes of Health, Bethesda, Md. Product: cAd3-EBO Business: Infectious Molecular target: NA Description: Recombinant chimpanzee adenovirus type 3 (ChAd3…

    Published on 12/8/2014
  • Cosentyx secukinumab: Additional Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Cosentyx secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: Treat …

    Published on 12/8/2014
  • Cosentyx secukinumab: Additional Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Cosentyx secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: Treat …

    Published on 12/8/2014
  • Daklinza daclatasvir: Phase III data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Daklinza daclatasvir (BMS-790052) Business: Infectious Molecular target: HCV NS5A protein Description: Selective HCV NS5A protein inhibitor Indication: Treat …

    Published on 12/8/2014
  • Decapeptyl triptorelin pamoate: Additional Phase III data

    Debiopharm Group, Lausanne, Switzerland Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Actavis plc (NYSE:ACT), Dublin, Ireland Product: Decapeptyl triptorelin pamoate (Debio 8206 SC) Business: …

    Published on 12/8/2014
  • Elafin: Phase II data

    Proteo Inc. (OTCQB:PTEO), Irvine, Calif. Minapharm Pharmaceuticals S.A.E., Cairo, Egypt Product: Elafin Business: Inflammation Molecular target: Elastase Description: Natural antagonist of elastase and proteinase-3 …

    Published on 12/8/2014
  • GWP42003: Phase IIa data

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: GWP42003 Business: Autoimmune Molecular target: NA Description: Cannabidiol containing tetrahydrocannabinol (THC) Indication: Treat ulcerative …

    Published on 12/8/2014
  • HLD-200: Phase III data

    Highland Therapeutics Inc., Toronto, Ontario Product: HLD-200 Business: Neurology Molecular target: NA Description: Modified-release formulation of the generic methylphenidate Indication: Treat ADHD Endpoint: Control of…

    Published on 12/8/2014
  • Idarucizumab dabigatran antidote: Clinical trial data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Idarucizumab dabigatran antidote (BI 655075) Business: Hematology Molecular target: NA Description: Fab fragment against dabigatran Indication: Reverse …

    Published on 12/8/2014
  • NNZ-2566: Phase II data

    Neuren Pharmaceuticals Ltd. (ASX:NEU; Pink:NURPF), Camberwell, Australia Product: NNZ-2566 Business: Neurology Molecular target: Not available Description: Synthetic analog of glycine-proline-glutamate which is derived …

    Published on 12/8/2014
  • Optune: Interim Phase III data

    Novocure Ltd., Isle of Jersey Product: Optune (NovoTTF-100A) Business: Cancer Molecular target: NA Description: Non-invasive portable device that disrupts the division of cancer cells in the brain using alternating …

    Published on 12/8/2014
  • Oral neratinib: Phase II data

    Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (…

    Published on 12/8/2014
  • Rociletinib: Phase I/II data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: Rociletinib (AVL-301) (formerly CO-1686) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) …

    Published on 12/8/2014
  • Secukinumab: Additional Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (Cosentyx) (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: …

    Published on 12/8/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993